Online ISSN: 2515-8260

ROLE OF HOMOEOPATHY IN MANAGEMENT OF COVID-19 COMPLICATIONS

Main Article Content

Dr. Gaurav Gupta,Dr. Hemant Vyas,Dr. Ravi Jain,Dr. Bharat Sharma,

Abstract

First time on December 30, 2019, a report of a cluster of pneumonia of unknown aetiology was published on ProMED-mail, possibly related to contact with a seafood market in Wuhan, China. [1] Following this till October 15, 2020, 38,394,169 confirmed cases of COVID-19, including 1,089,047 deaths have been reported to World Health Organization. [2] First time, this case was reported on December 31, 2019 by WHO Country Office in China but based on symptoms; its beginning can be traced in initial days of December 2019. Initially for first few cases (n=29), this infection was classified as "pneumonia of unknown etiology." Following intensive outbreak investigation by the Chinese Center for Disease Control and Prevention (CDC) and local CDCs, this infection was classified as novel viral infection belonging to the coronavirus (CoV) family. Finally on February 11, 2020, the WHO Director-General, Dr. Tedros Adhanom Ghebreyesus, announced that the disease caused by this new CoV was a "COVID-19," which is the acronym of "coronavirus disease 2019". [3] This Coronaviruses are encapsulated, single-stranded RNA viruses that generally cause mild, cold-like illnesses in human beings and belongs to SARS-coronavirus-2 (SARS-CoV-2). [4] Since December 2019, COVID-19 information has much evolved. Much information has been gathered about its transmission, symptomatology, diagnosis, treatment and prevention. Many clinical trials are undergoing regarding its vaccination. Along with this, many case reports have suggested about probable complications which arises during either the stage of illness or convalescence periods. These long-term effects of surviving COVID-19 have become a new focus of attention for clinicians and researchers. [5]

Article Details